CN104203901A - 治疗炎症的组合物和方法 - Google Patents

治疗炎症的组合物和方法 Download PDF

Info

Publication number
CN104203901A
CN104203901A CN201080026180.0A CN201080026180A CN104203901A CN 104203901 A CN104203901 A CN 104203901A CN 201080026180 A CN201080026180 A CN 201080026180A CN 104203901 A CN104203901 A CN 104203901A
Authority
CN
China
Prior art keywords
compound
alkyl
certain embodiments
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080026180.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·约斯图普
C·E·施瓦兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolvyx Pharmaceuticals Inc
Original Assignee
Resolvyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals Inc filed Critical Resolvyx Pharmaceuticals Inc
Publication of CN104203901A publication Critical patent/CN104203901A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201080026180.0A 2009-04-13 2010-04-13 治疗炎症的组合物和方法 Pending CN104203901A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16873909P 2009-04-13 2009-04-13
US61/168,739 2009-04-13
US17480609P 2009-05-01 2009-05-01
US61/174,806 2009-05-01
PCT/US2010/030813 WO2010120719A1 (en) 2009-04-13 2010-04-13 Compositions and methods for the treatment of inflammation

Publications (1)

Publication Number Publication Date
CN104203901A true CN104203901A (zh) 2014-12-10

Family

ID=42982804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080026180.0A Pending CN104203901A (zh) 2009-04-13 2010-04-13 治疗炎症的组合物和方法

Country Status (15)

Country Link
US (2) US8673881B2 (https=)
EP (1) EP2419399B1 (https=)
JP (1) JP5785537B2 (https=)
CN (1) CN104203901A (https=)
AU (1) AU2010236663B2 (https=)
BR (1) BRPI1011325A2 (https=)
CA (1) CA2758586A1 (https=)
CL (1) CL2011002548A1 (https=)
ES (1) ES2576086T3 (https=)
IL (1) IL215592A (https=)
MX (1) MX2011010827A (https=)
NZ (1) NZ596228A (https=)
RU (1) RU2543720C2 (https=)
TW (1) TW201039815A (https=)
WO (1) WO2010120719A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287480A (zh) * 2015-10-28 2016-02-03 西安医学院第一附属医院 Resolvin D1作为抗癫痫药物的应用
CN110709091A (zh) * 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
CN110988180A (zh) * 2019-12-19 2020-04-10 山东达因海洋生物制药股份有限公司 一种基于杂质谱的埃索美拉唑镁的有关物质分析方法
CN114269901A (zh) * 2019-08-27 2022-04-01 赛琳技术有限公司 用于治疗肢体缺血的激活的间充质干细胞
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
RU2497498C2 (ru) * 2012-02-14 2013-11-10 Константин Николаевич Руссков Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
WO2014030132A2 (en) 2012-08-22 2014-02-27 Universidad De Los Andes Use of statins for periodontal disease and bone regeneration
WO2014063105A1 (en) * 2012-10-19 2014-04-24 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
HK1219654A1 (zh) 2013-02-22 2017-04-13 University Of Southern California 用於治疗眼科疾病和病症的方法
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
WO2016144569A1 (en) 2015-03-10 2016-09-15 Elc Management Llc Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways
CN107445821A (zh) * 2017-08-11 2017-12-08 上海中医药大学 聚炔酸类衍生物
CN112955145A (zh) 2018-09-04 2021-06-11 密涅瓦神经科学有限公司 使用苯氧丙胺化合物治疗疼痛的方法
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
WO2023250031A1 (en) * 2022-06-21 2023-12-28 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
AU2002349297A1 (en) 2001-12-03 2003-06-17 Kobenhavns Amt Statin-like compounds
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
DE102008027146B4 (de) 2008-06-02 2012-01-19 Ing. Erich Pfeiffer Gmbh Austragvorrichtung
WO2010039531A1 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds
US8619544B2 (en) 2008-09-23 2013-12-31 Qualcomm Incorporated Apparatus and method for facilitating transmit diversity for communications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287480A (zh) * 2015-10-28 2016-02-03 西安医学院第一附属医院 Resolvin D1作为抗癫痫药物的应用
CN105287480B (zh) * 2015-10-28 2019-01-11 西安医学院第一附属医院 Resolvin D1作为抗癫痫药物的应用
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN110709091A (zh) * 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
CN114269901A (zh) * 2019-08-27 2022-04-01 赛琳技术有限公司 用于治疗肢体缺血的激活的间充质干细胞
CN110988180A (zh) * 2019-12-19 2020-04-10 山东达因海洋生物制药股份有限公司 一种基于杂质谱的埃索美拉唑镁的有关物质分析方法

Also Published As

Publication number Publication date
EP2419399A4 (en) 2012-08-29
US8673881B2 (en) 2014-03-18
CL2011002548A1 (es) 2012-07-20
MX2011010827A (es) 2012-01-20
CA2758586A1 (en) 2010-10-21
BRPI1011325A2 (pt) 2016-03-15
AU2010236663B2 (en) 2015-08-20
IL215592A0 (en) 2011-12-29
EP2419399B1 (en) 2016-03-23
US20120101061A1 (en) 2012-04-26
US9315447B2 (en) 2016-04-19
IL215592A (en) 2017-02-28
JP5785537B2 (ja) 2015-09-30
AU2010236663A1 (en) 2011-11-24
RU2543720C2 (ru) 2015-03-10
WO2010120719A1 (en) 2010-10-21
NZ596228A (en) 2014-01-31
US20140275247A1 (en) 2014-09-18
JP2012523459A (ja) 2012-10-04
TW201039815A (en) 2010-11-16
ES2576086T3 (es) 2016-07-05
HK1166305A1 (zh) 2012-10-26
EP2419399A1 (en) 2012-02-22
RU2011146005A (ru) 2013-05-20

Similar Documents

Publication Publication Date Title
JP5785537B2 (ja) 炎症を処置するための組成物及び方法
WO2010039531A1 (en) Therapeutic compounds
US20070254897A1 (en) Compositions and methods for the treatment of cardiovascular disease
JP2005533840A (ja) ヒストン脱アセチル化酵素阻害剤としての新規な化合物
CN103917093B (zh) 视蛋白结合配体、组合物及使用方法
WO2010091226A1 (en) Compositions and methods for organ preservation
JP2022062115A (ja) ｓＧＣ刺激剤のリンプロドラッグ
KR20050085563A (ko) 하부요로증상을 치료하기 위한 알파-2-델타 리간드
JP2024122966A (ja) 芳香族化合物およびその医薬用途
JP2002167329A (ja) 軟骨障害を処置する方法
JP2007517841A (ja) １，３−ジフェニルプロプ−２−エン−１−オン誘導体化合物、その調製方法およびその使用
EP3091972A1 (en) Method of treating liver disorders
US20110245528A1 (en) Therapeutic compounds
US20020151734A1 (en) 12-HETrE analogs and methods of use thereof
JP7831858B2 (ja) 保護されたｈｄａｃ（ヒストン脱アセチル化酵素）阻害剤
HK1166305B (en) Compositions and methods for the treatment of inflammation
TW201311636A (zh) 用於治療自體免疫發炎疾病之化合物
JP2023518205A (ja) 酸化ストレスと関連した障害の処置およびこの処置のための化合物
EP1596845A1 (fr) Utilisation therapeutique de glycerols acyles et de leurs analogues azotes et sulfures
WO2005005433A1 (ja) 高カルシウム血症および骨疾患治療剤
EP2981521A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141210

WD01 Invention patent application deemed withdrawn after publication